Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Comment by nozzpackon Nov 14, 2020 9:35am
178 Views
Post# 31900957

RE:Bausch Reports Strong Sales Growth for Trulance

RE:Bausch Reports Strong Sales Growth for TrulanceBausch did not report quarterly sales of Trulance for 2020 but 2019 Trulance sales were $55 million US = $70 m CAD, which was not for a full year .

As sales efforts in the US are still ramping up along with Strong growth in all quarters in 2020 , US sales of Trulance are likely to have an annualized revenue rate of $100 million US ($130 m cad ) in Q4 of 2020.

Canadian sales typically fall in the 10% to %15 % of US sales.

These statistics suggest that Canadian sales of Trulance in Canada will be above $10 million cad/year  and probably settle in the $15 million level.

This will transform Ciphers growth outlook and market cap outlook.

The continuing discussions with Bausch on the Trulance status probably relates to just how much compensation / offer Cipher will get...


<< Previous
Bullboard Posts
Next >>